Product NDC: | 51991-074 |
Proprietary Name: | Ascomp with Codeine |
Non Proprietary Name: | Butalbital, Aspirin, Caffeine and Codeine Phosphate |
Active Ingredient(s): | 325; 50; 40; 30 mg/1; mg/1; mg/1; mg/1 & nbsp; Butalbital, Aspirin, Caffeine and Codeine Phosphate |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 51991-074 |
Labeler Name: | Breckenridge Pharmaceutical, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA075231 |
Marketing Category: | ANDA |
Start Marketing Date: | 20090501 |
Package NDC: | 51991-074-05 |
Package Description: | 500 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-05) |
NDC Code | 51991-074-05 |
Proprietary Name | Ascomp with Codeine |
Package Description | 500 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-05) |
Product NDC | 51991-074 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Butalbital, Aspirin, Caffeine and Codeine Phosphate |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20090501 |
Marketing Category Name | ANDA |
Labeler Name | Breckenridge Pharmaceutical, Inc. |
Substance Name | ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
Strength Number | 325; 50; 40; 30 |
Strength Unit | mg/1; mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Barbiturate [EPC],Barbiturates [Chemical/Ingredient],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient] |